1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Optic tract hyperintensity on T2-weighted images among patients with pituitary macroadenoma: correlation with visual impairment
Patient No./Age (y)/SexDurationSize (mm)OCASVADVFDPathologyIAT
1/36/M2 mo18−−−+
2/61/M9 y23.7+−+ (rt 0.7, lt blind)+PA−
3/42/F16 mo26.5++++ (rt 0.02, lt 1.5)+PA (corticotro)−
4/38/F10 mo14−−−+
5/40/M6 mo35++++ (rt 0.07, lt 0.05)+PA (null)−
6/55/F4 y46++++ (rt 0.06, lt 0.06)+PA (chromophobe)−
7/65/F2 mo13−−−+PA (null)
8/74/M18 mo16.4+++ (rt 0.7, lt 0.4)+PA (null)−
9/54/F3 mo27+++ (rt 0.06, lt 0.1)+PA (nonfunctioning)+ (rt 1.2, lt 0.8)
10/65/M2 mo13−++ (rt light sense)+Pituitary carcinoma−
11/59/F14 mo35++++ (rt 0.3, lt 0.9)+PA (null)−
12/55/M3 mo22++++ (rt 0.5, lt 0.1)+PA+ (rt 1.0, lt 1.0)
13/41/F19 mo25++++ (hand sense)+PA (null)−
14/37/F3 mo16−−−+
15/70/F6 mo18+++ (rt 0.1, lt blind)−
16/27/M6 mo15−++ (finger sense)+PA (chromophobe)+ (rt 0.7, lt 0.9)
17/58/M26 mo24++++ (rt 1.5, lt 0.4)−PA (null)−
18/21/F8 mo30+−−+PA (GH)−
19/50/F10 y51++++ (rt 0.03, lt 0.1)+PA(FSH-LH)−
20/74/F1.5 mo18−++ (lt light sense)−PA (prolactinoma)+ (rt 0.8, lt 0.4)
21/66/F2 mo15−−−−PA (null)
22/63/M2 mo23.7++++ (rt 0.1, lt 0.7)+PA (chromophobe)+ (rt 0.7, lt 0.8)
23/54/F3 mo13−−−−PA
24/56/F3 mo20−−−−PA
25/45/M2 mo16−−−+PA (chromophobe)
26/36/M2 mo12.2−−−−
27/50/M3 mo16++++ (rt 0.9, lt 0.3)+PA (GH)+ (rt 0.9, lt 0.7)
  • Note.—OC indicates optic chiasm compression; AS, abnormal signal in optic nerve; VAD, visual acuity disturbance; VFD, visual field disturbance; IAT, improvement of visual acuity after treatment; PA, pituitary adenoma; FSH-LH, follicle stimulating hormone-luteinizing hormone; GH, growth hormone.